10X Genomics (TXG) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
24 Apr, 2026Executive summary
Annual meeting scheduled for June 4, 2026, with voting open until June 3, 2026, at 11:59 PM ET.
Shareholders can access proxy materials online or request paper/email copies by May 21, 2026.
Meeting will be held virtually, with instructions provided for online participation.
Voting matters and shareholder proposals
Election of three Class I directors for a three-year term expiring at the 2029 annual meeting.
Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory vote to approve compensation of named executive officers.
Other business may be addressed as appropriate during the meeting.
Board of directors and corporate governance
Nominees for Class I director positions: Serge Saxonov, Benjamin J. Hindson, and John R. Stuelpnagel.
Directors to serve until the 2029 annual meeting if elected.
Latest events from 10X Genomics
- 2026 proxy covers director elections, auditor ratification, and executive pay, with strong governance focus.TXG
Proxy filing24 Apr 2026 - Atera delivers high-throughput, single-cell spatial transcriptomics with unmatched flexibility.TXG
Corporate presentation19 Apr 2026 - Consumables growth and cost discipline drove revenue above guidance as losses narrowed.TXG
Q4 202513 Apr 2026 - Innovation and strong cash flow drive growth amid macro challenges and evolving customer needs.TXG
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Spatial consumables growth drove 4% revenue gain; 2024 guidance lowered amid macro headwinds.TXG
Q2 20242 Feb 2026 - Strong product launches and sales reorganization position the company for scalable growth.TXG
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Q3 2024 revenue fell 1%, with strong consumables growth and new launches amid market headwinds.TXG
Q3 202418 Jan 2026 - Despite a tough 2024, new products and restructuring set the stage for robust future growth.TXG
Wolfe Research Healthcare Conference 202413 Jan 2026 - Strong 2025 results, innovation, and AI partnerships drive growth despite capital market headwinds.TXG
44th Annual J.P. Morgan Healthcare Conference12 Jan 2026